biopharmaapac.com
Cure8 news brief
Fresenius Kabi's Vedolizumab Biosimilar Clears FDA and EMA Review Milestone
Medications
Vedolizumab
Biosimilars
Anti Integrin
Regulatory Update
Patients On Biologics
Clinicians
Researchers
Why This Matters
If approved, a vedolizumab biosimilar could increase treatment options and potentially lower costs or improve access to an established biologic used for moderate-to-severe Crohn’s disease and ulcerative colitis. Regulatory review acceptance is an early but important step toward possible future availability.
Who Should Pay Attention
Adults with moderate-to-severe Crohn’s disease or ulcerative colitis; patients currently using or considering vedolizumab/Entyvio; clinicians who prescribe biologics; health systems and payers focused on biosimilar access.
Study Snapshot
Story typeBusiness news
Evidence typeRegulatory update
Source depthFull source text
What To Know
Fresenius Kabi announced that regulatory authorities (FDA and EMA) have accepted for review applications for PB016, a proposed vedolizumab biosimilar (IV) licensed from Polpharma Biologics. The filings cover a lyophilized vial for IV administration and the company says the submission is supported by a comprehensive biosimilarity development program.
The candidate targets the same indications as the reference product Entyvio (vedolizumab): moderately to severely active ulcerative colitis and Crohn’s disease in adults. This is a regulatory milestone — acceptance for review — not an approval or availability announcement.
Timelines, review outcomes, and any post-marketing plans (including pricing and formulary coverage) are not provided in the source. The article frames the filing as part of Fresenius’ broader biosimilars and commercial strategy.
Keep In Mind
This article reports acceptance of regulatory filings for review, not approval. Acceptance means the agencies will evaluate the application but does not indicate outcome or timing. The piece is a company announcement from a biopharma news site and summarizes the sponsor’s statements and strategy.
Source Details
Review the original publication for the complete reporting, methods, and context.
Publicationbiopharmaapac.com
Indexed viaGoogle News
Source typeWeb article
PublishedAug 3, 2026, 11:54 PM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 ... - Morningstar
If approved, a vedolizumab biosimilar could increase access to an established IBD biologic by offering a lower-cost alternative, potentially reducing barriers to starting or continuing treatment for people with...
Polpharma Biologics gains FDA and EMA review acceptances - PharmaTimes
A vedolizumab biosimilar could increase access to an important biologic treatment for people with moderate‑to‑severe UC and Crohn’s disease by offering a potentially lower‑cost alternative. Regulatory review by the FDA...
Fresenius Announces FDA and EMA Acceptance for Review of Vedolizumab Biosimilar Candidate
Accepted applications for a vedolizumab biosimilar could lead to another treatment option for adults with moderate‑to‑severe ulcerative colitis and Crohn’s disease and may improve access or affordability if approved.